Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Elekta AB ( ($SE:EKTA.B) ) just unveiled an announcement.
Elekta has achieved a significant milestone with over two million patients treated using the Leksell Gamma Knife radiosurgery, a non-invasive alternative to open brain surgery for conditions like brain tumors and neurological disorders. This achievement underscores the impact of Gamma Knife technology in transforming patient care, enhancing quality of life, and maintaining Elekta’s position as a leader in the stereotactic radiosurgery market.
The most recent analyst rating on ($SE:EKTA.B) stock is a Hold with a SEK50.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.
More about Elekta AB
Elekta is a leader in precision radiation therapy, dedicated to providing the best cancer care through innovative, sustainable, and cost-efficient solutions. Headquartered in Stockholm, Sweden, Elekta collaborates globally to improve patient outcomes and is listed on Nasdaq Stockholm.
Average Trading Volume: 940,835
Technical Sentiment Signal: Sell
Current Market Cap: SEK19.33B
Learn more about EKTA.B stock on TipRanks’ Stock Analysis page.